iBio (NYSE AMERICAN:IBIO) appointed senior biopharma executive, Dr. Alexandra Kropotova, as a director and a member of the board’s new science and technology committee.
Dr. Kropotova has expertise in all phases of global clinical development, translational medicine and medical affairs. As vice president, global specialty R&D, respiratory and inflammation therapeutic area at Teva Pharmaceuticals (TASE:TEVA), she is responsible for leading the design and execution of global clinical development programs, the majority of which are biologic candidates for pulmonary, chronic inflammatory or autoimmune indications.
“We are pleased to welcome Dr. Kropotova to our board and value her vast biologics development experience across multiple therapeutic areas,” Tom Isett, iBio’s chairman and CEO, said in a statement.
“Her strategic portfolio planning insights should be an invaluable asset to iBio’s science and technology committee as we continue to expand our biopharmaceutical development activities in pulmonology, oncology, and fibrotic diseases,” he added.
